Country: কানাডা
ভাষা: ইংরেজি
সূত্র: Health Canada
LANTHANUM (LANTHANUM CARBONATE HYDRATE)
TAKEDA CANADA INC
V03AE03
LANTHANUM CARBONATE
250MG
TABLET (CHEWABLE)
LANTHANUM (LANTHANUM CARBONATE HYDRATE) 250MG
ORAL
100
Prescription
PHOSPHATE-REMOVING AGENTS
Active ingredient group (AIG) number: 0151709001; AHFS:
CANCELLED POST MARKET
2023-04-25
_ _ _ _ _FOSRENOL_ _®_ _ Product Monograph _ _Page 1 of 32_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION FOSRENOL® lanthanum carbonate hydrate Chewable tablets, 250 mg, 500 mg, 750 mg, and 1000 mg, oral Phosphate binder ATC code: V03A E03 Takeda Canada Inc. 22 Adelaide Street West, Suite 3800 Toronto Ontario M5H 4E3 Date of Initial Authorization: December 14, 2012 Date of Revision: April 06, 2023 Submission Control Number: 270959 FOSRENOL® and the FOSRENOL Logo are registered trademarks of Shire International Licensing BV, a Takeda company. TAKEDA® and the TAKEDA Logo are registered trademarks of Takeda Pharmaceutical Company Limited, used under license. _ _ _ _ _ _ _FOSRENOL_ _®_ _ Product Monograph _ _Page 2 of 32_ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS, Gastrointestinal 04/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . [To update, right-click anywhere in the Table of Contents and select “Update Field”, “Update entire table”, click OK.] RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS ............................................................................................................... 4 1.1 Pediatrics ................................................................................................................ 4 1.2 Geriatrics ................................................................................................................ 4 2 CONTRAINDICATIONS ................................................................................................. 4 4 DOSAGE AND ADMINISTRATION ................................................................................. সম্পূর্ণ নথি পড়ুন